Comparação Dos Gastos Em Saúde Por Linfoma Não-Hodgkin Antes E Durante a Pandemia Do Covid-19

Silva, Ajme; Castro, Lms; Gonçalves, Pgn; Silva, AL; Pinheiro, EN; Reis, Gsc; Mota, LO; Assayag, Ppc; Santos, Rmpd; Berg, A. van der

doi:10.1016/j.htct.2021.10.116

Hematology, Transfusion and Cell Therapy

2021

DOI: 10.1016/j.htct.2021.10.116

|View full text |Cite

Comparação Dos Gastos Em Saúde Por Linfoma Não-Hodgkin Antes E Durante a Pandemia Do Covid-19

Ajme Silva

Lms Castro

Pgn Gonçalves

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil

Sachetti,

Barbosa,

de Carvalho

et al. 2024

Cytotherapy

View full text Add to dashboard Cite

Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil

Sachetti,

Barbosa,

de Carvalho

et al. 2024

Cytotherapy

View full text Add to dashboard Cite

The translational gap for gene therapies in low- and middle-income countries

Doxzen,

Adair,

Fonseca Bazzo

et al. 2024

Sci. Transl. Med.

View full text Add to dashboard Cite

Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the potential to become safe and effective treatment options for a wide range of genetic and nongenetic diseases. However, as the medical scope of gene therapies expands, consideration must be given to those who will benefit and what proactive steps must be taken to widen development and access potential, particularly in regions carrying a high disease burden.

show abstract

State-of-the-art knowledge on the regulation of advanced therapy medicinal products

2022

View full text Add to dashboard Cite

Advanced therapy medicinal products (ATMPs) constitute therapeutic agents based on obtained cells, tissues or genes representing a novel treatment opportunity in medicine. In addition, ATMPs are administered into the cells or tissues of humans from the patient's own cells, donors, or genetically modified cells. Recently, the field of developing ATMPs has become a point of attention due to the clinical efficacy expected in defeating incurable diseases such as cancers and neurodegenerative disorders. Currently, there are two modes regarding the distribution of ATMPs. First, ATMPs that might be legally authorized for marketing. Second, the patients are able to access unapproved ATMPs through the hospital exemption (HE) or clinical practice program or through the compassionate use and expanded access program. The aim of this review is to discuss state-of-the-art knowledge on the regulation of ATMPs and provide regulatory recommendations.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparação Dos Gastos Em Saúde Por Linfoma Não-Hodgkin Antes E Durante a Pandemia Do Covid-19

Cited by 3 publications

References 0 publications

Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil

Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil

The translational gap for gene therapies in low- and middle-income countries

State-of-the-art knowledge on the regulation of advanced therapy medicinal products

Contact Info

Product

Resources

About